Navigation Links
First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A),Significantly Improves Idiopathic Detrusor Overactivity (IDO) in,Patients With Symptoms of Overactive Bladder

BTX-A also significantly improved all secondary endpoints, including measures of bladder filling and pressure; urination frequency, urgency urinary incontinence episodes, and urgency (at 4 weeks only); and QoL. All these improvements were significantly greater than with placebo vs. baseline.

The extension study lasting until week 24 suggested that most of these beneficial effects of BTX-A were maintained for at least 24 weeks. At baseline, 81% of patients in the BTX-A group were experiencing urgent urinary incontinence daily, but urinary frequency normalized in 57% at 4 weeks, and 36% maintained this benefit at 24 weeks; further, 50% were continent at follow-up, and the improvement lasted 24 weeks. Complete resolution of detrusor overactivity was observed in 44% of BTX-A patients at 4 weeks, though this dropped to 25% by 24 weeks.

Quality of life was assessed using the IIQ-7 and UDI-6 and was significantly better in the BTX-A group compared with placebo at both 4 and 12 weeks post-injections.

Treatment with BTX-A was well tolerated and there were no major complications. Six patients in the BTX-A group had symptomatic post void residual (PVR) at follow-up requiring clean intermittent self catheterization (CISC). Seven patients developed symptomatic urinary tract infection, six of whom were performing CISC. Mr. Sahai's and Mr. Dasgupta's co-researcher was Mohammad S. Khan, FRCS (urol) FEBU, consultant urologist at Guy's Hospital, London. BTX-A is not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of any form of OAB, nor is it currently approved for this use by regulatory agencies in Europe. This research was funded by Allergan, Inc and through a project grant from the British Urological Foundation.

    (1) National Diabetes Information Clearinghouse, a service of the National

        Institute of Diabetes and Digestive and Kidney Disease (DIDDK), NIH,

        




Page: 1 2 3 4 

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than
Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized
Patients Surveyed are at Risk for VTE and Many do not Receive
Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in
Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/18/2013)... ORLANDO, Fla. , May 18, 2013 ... and are considered the most sensitive method for ... completely effective in preventing cancer cases 3 . EndoChoice ... its new Fuse™ system significantly improves the accuracy of ... missed by colonoscopists. EndoChoice will be discussing these clinical ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/18/2013)... , May 18, 2013 Faruqi & ... is investigating potential securities fraud at AVEO Pharmaceuticals, ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... its executives violated federal securities laws by issuing ... Phase III drug trials for Tivopath (tivozanib) (titled ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... safety data from VELOUR, the pivotal Phase III trial ... metastatic colorectal cancer (mCRC) will be presented by Edith ... Angiogenesis Foundation,s 9th Annual M. Judah Folkman International Conference: ... 2011 at the Hyatt Regency Cambridge. The ...
... Inc. (NYSE Amex: PIP ) today announced ... in the Delaware Court of Chancery. PharmAthene filed the ... in ST-246, an orally available smallpox antiviral drug candidate. ... decision," remarked Eric I. Richman, President and Chief Executive ...
Cached Medicine Technology:Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundation's 2011 M. Judah Folkman International Conference in Cambridge, Mass. 2PharmAthene Awarded 50% Profit Split on Worldwide Sales of Smallpox Antiviral Therapy by Delaware Chancery Court 2PharmAthene Awarded 50% Profit Split on Worldwide Sales of Smallpox Antiviral Therapy by Delaware Chancery Court 3
(Date:5/18/2013)... TheBeautyPlace.com answers important questions about the ... not a result of stress, nutrient deficiency or wearing ... 70% of men suffer from male patterned baldness. ... for hair transplant surgery, but additionally carries a hair ... as Bosley Professional Strength. Their product line is a ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Although obesity ... tumors, the association between obesity and esophageal adenocarcinoma, a ... other obesity-related tumors. As reported on Cancer.gov, ... are almost twice as likely as those of normal ... the relationship between obesity and esophageal cancer is not ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The “Sleep ... Pulse Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, ... Forecast to 2017” analyzes and studies the major market ... and Rest of the World. , Browse , ... 16 Figures , 318 ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Adolescents, especially ... known as “Spice” or “K2” are landing in emergency ... to curb this drug epidemic with a new ... marijuana. , According to research from the National Institute ... popular illegal drug among American teenagers. In 2012, 11 ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... initiatives designed to improve the management of rheumatoid arthritis ... the Annual Congress of the European League Against Rheumatism ... impact score , The first, a EULAR initiative entitled ... Impact of Disease, (RAID) score, was based on patients, ...
... Injury Is Key, WASHINGTON, June 13 ... will fly to Germany on Saturday,to work with ... in,assessing their current rehabilitation practices. They will also ... care given to,injured soldiers and other military personnel ...
... Rising Medical Solutions, Inc.,(Rising), a leading medical-financial ... have chosen Bank of America as their ... management offerings., (Logo: http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ), ... America Direct(R) treasury,services as the foundation for ...
... knowledge of safety, privacy, emergency practices, but will leave them ... parents leave their tweens home alone for an extended period ... to 13-year-olds have the knowledge or skills to stay safe, ... C.S. Mott Children,s Hospital National Poll on Children,s Health ...
... EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-stage ... cancer and inflammatory diseases,announced today that James ... present a Company overview during the Business ... International Convention,being held June 17-20, 2008 at ...
... (PAH)chronically high blood pressure in the blood vessels of ... or HN) have a very poor chance of survival ... to new research from the University of Pennsylvania. ... advanced left heart failure but has never been demonstrated ...
Cached Medicine News:Health News:New insight into RA patient priorities and motivators for clinical trial involvement 2Health News:New insight into RA patient priorities and motivators for clinical trial involvement 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:Rising Medical Solutions Chooses Bank of America to Bring Enhanced Cash Management and Provider Payment Solutions to the Marketplace 2Health News:Rising Medical Solutions Chooses Bank of America to Bring Enhanced Cash Management and Provider Payment Solutions to the Marketplace 3Health News:Parents Worry About Tweens Left Alone 2Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:Serum sodium predicts mortality 10 times higher in PAH patients 2
HDL Cholesterol, liquid....
For the quantitative determination of high density lipoprotein (HDL) in human serum....
... Intended for the ... in plasma. Two vials, ... Enzymatic, alphaketoglutarate. Uses NADPH ... other plasma compounds. Reaction: ...
... The Proteomeworks system is an ... technologies that enables protein function ... sample preparation, 2-D electrophoresis, staining, ... excision, automated protein digestion, mass ...
Medicine Products: